ES2156444T3 - Nuevos compuestos. - Google Patents
Nuevos compuestos.Info
- Publication number
- ES2156444T3 ES2156444T3 ES98924708T ES98924708T ES2156444T3 ES 2156444 T3 ES2156444 T3 ES 2156444T3 ES 98924708 T ES98924708 T ES 98924708T ES 98924708 T ES98924708 T ES 98924708T ES 2156444 T3 ES2156444 T3 ES 2156444T3
- Authority
- ES
- Spain
- Prior art keywords
- pct
- sec
- new compounds
- date
- pub
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Valve-Gear Or Valve Arrangements (AREA)
- Liquid Crystal (AREA)
Abstract
Un compuesto de fórmula I o una sal del mismo: (I) **fórmula** en la cual: A es un anillo heterocíclico de 5 miembros que contiene 1 a 3 heteroátomos seleccionados de nitrógeno, oxígeno o azufre; R1 es (CH2)nCO2H donde n es 1 ó 2, (CH2)q tetrazol-5-ilo donde q es 0, 1 ó 2 o R1 es COR3 donde R3 es amino, alquilamino, dialquilamino, NHOalquilo, NHSO2alquilo, OH, N(CH2CO2H)2 o un grupo de fórmula (i): (i) **fórmula** en la cual p es 1 ó 2, o R 3 es un grupo de fórmula (ii): (ii) **fórmula** donde B es un anillo heterocíclico de 5 miembros que contiene 1a 4 heteroátomos seleccionados de nitrógeno, oxígeno o azufre y R8 es hidrógeno o un grupo CH2CO2H, CH2CON(CH2CO2H)2 o CH2COR9 donde R9 es un grupo de fórmula (i) como se ha definido anteriormente o un grupo de fórmula (iii): **fórmula** R2 es un grupo de fórmula (iv) o (v): (iv) **fórmula** (v) **fórmula** donde los grupos R4 son independientemente hidrógeno, halógeno, metoxi, metiltio o alquilo C1-2 (sustituido opcionalmente con uno o más átomos de fluor); los grupos R5 son independientemente hidrógeno, halógeno, hidroxi, alquiltio C1-3, alquilo C1-4 (sustituido opcionalmente con uno o más átomos de fluor), cicloalquilo C3-4, MeOCH2, MeSCH2 o alcoxi C1-2; los grupos R6 son independientemente hidrógeno, halógeno o metilo (sustituido opcionalmente con uno o más átomos de fluor); Z1 es CH=CH, CF=CH o CF=CF; Z2 es un enlace simple, oxígeno, azufre, CH2CH=CH, CH2CH=CHCH2 o un grupo alquileno C1-4 interrumpido opcionalmente por un átomo de oxígeno o de azufre; R7 es hidrógeno, halógeno, alquilo C1-2, CF3 o un grupo metiltio; Q1 y Q2 representan cada uno independientemente O o S; con la condición de que, cuando Q1 es oxígeno, R2 es un grupo de fórmula (iv).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9702002A SE9702002D0 (sv) | 1997-05-28 | 1997-05-28 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2156444T3 true ES2156444T3 (es) | 2001-06-16 |
Family
ID=20407125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98924708T Expired - Lifetime ES2156444T3 (es) | 1997-05-28 | 1998-05-18 | Nuevos compuestos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US6162808A (es) |
EP (1) | EP0984963B1 (es) |
JP (1) | JP2002501528A (es) |
AT (1) | ATE200489T1 (es) |
AU (1) | AU7681198A (es) |
DE (1) | DE69800699T2 (es) |
DK (1) | DK0984963T3 (es) |
ES (1) | ES2156444T3 (es) |
GR (1) | GR3036195T3 (es) |
PT (1) | PT984963E (es) |
SE (1) | SE9702002D0 (es) |
WO (1) | WO1998054180A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999026944A1 (en) * | 1997-11-21 | 1999-06-03 | Astrazeneka Uk Limited | New compounds which are p2-purinoceptor 7-transmembrane (tm) g-protein coupled receptor antagonists |
US7696168B2 (en) * | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
EP2336169A1 (en) | 2000-04-21 | 2011-06-22 | New England Medical Center Hospital | G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same |
US20030151980A1 (en) * | 2002-02-13 | 2003-08-14 | Isador Farash | Color referenced multi-time watch |
AUPS160602A0 (en) | 2002-04-08 | 2002-05-16 | University Of Queensland, The | Therapeutic method |
AU2002952086A0 (en) * | 2002-10-16 | 2002-11-07 | The University Of Queensland | Treatment of osteoarthritis |
BRPI0517058A (pt) * | 2004-11-04 | 2008-09-30 | New England Medical Center Inc | agonistas e antagonistas do receptor acoplado à proteìna g e métodos de uso |
US7589213B2 (en) | 2007-04-27 | 2009-09-15 | Old David W | Therapeutic substituted lactams |
WO2009140205A2 (en) | 2008-05-15 | 2009-11-19 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
CN103159641A (zh) * | 2011-12-14 | 2013-06-19 | 天津泰普药品科技发展有限公司 | 托伐普坦中间体2-甲酸-5-(2-甲基苯甲酰氨基)甲苯的制备方法 |
EP2881390A1 (en) | 2013-12-04 | 2015-06-10 | Sanofi | Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase |
CN106045937B (zh) * | 2016-06-21 | 2019-04-16 | 杭州诺维和医药技术有限公司 | 一种{2-[2-(2-氨基-4-噻唑基)-乙酰基氨基]-4-噻唑基}-乙酸的合成方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2099868C (en) * | 1991-01-31 | 2002-04-02 | Thomas Richard Belliotti | Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines |
IT1277373B1 (it) * | 1995-07-28 | 1997-11-10 | Consiglio Nazionale Ricerche | Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato |
-
1997
- 1997-05-28 SE SE9702002A patent/SE9702002D0/xx unknown
-
1998
- 1998-05-18 PT PT98924708T patent/PT984963E/pt unknown
- 1998-05-18 ES ES98924708T patent/ES2156444T3/es not_active Expired - Lifetime
- 1998-05-18 JP JP50056799A patent/JP2002501528A/ja active Pending
- 1998-05-18 US US09/091,187 patent/US6162808A/en not_active Expired - Fee Related
- 1998-05-18 AU AU76811/98A patent/AU7681198A/en not_active Abandoned
- 1998-05-18 DK DK98924708T patent/DK0984963T3/da active
- 1998-05-18 EP EP98924708A patent/EP0984963B1/en not_active Expired - Lifetime
- 1998-05-18 DE DE69800699T patent/DE69800699T2/de not_active Expired - Fee Related
- 1998-05-18 WO PCT/SE1998/000940 patent/WO1998054180A1/en active IP Right Grant
- 1998-05-18 AT AT98924708T patent/ATE200489T1/de not_active IP Right Cessation
-
2001
- 2001-07-10 GR GR20010401043T patent/GR3036195T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE200489T1 (de) | 2001-04-15 |
EP0984963B1 (en) | 2001-04-11 |
SE9702002D0 (sv) | 1997-05-28 |
EP0984963A1 (en) | 2000-03-15 |
US6162808A (en) | 2000-12-19 |
GR3036195T3 (en) | 2001-10-31 |
DE69800699D1 (de) | 2001-05-17 |
AU7681198A (en) | 1998-12-30 |
PT984963E (pt) | 2001-07-31 |
DK0984963T3 (da) | 2001-06-05 |
DE69800699T2 (de) | 2001-09-06 |
JP2002501528A (ja) | 2002-01-15 |
WO1998054180A1 (en) | 1998-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9702651D0 (sv) | Novel compounds | |
BR0015963A (pt) | Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos | |
EP0903349A3 (en) | CCR-3 receptor antagonists | |
DE69532162D1 (de) | Cannabinoid-rezeptor-antagonisten | |
ATE331726T1 (de) | Adenine-derivate | |
WO2003086303A3 (en) | Farnesoid x-activated receptor agonists | |
BR9915403A (pt) | Antagonistas receptores iii de 4-aroil-piperidin-ccr-3 | |
ES2158813A1 (es) | Sales cuaternarias de piperidina antagonistas del receptor ccr-3 | |
DE60012040D1 (de) | Trizyklische 1-benzylpyrazol-3-carbonsäurederivate als cannabinoidrezeptorantagonisten | |
ES2156444T3 (es) | Nuevos compuestos. | |
SE9702794D0 (sv) | New compounds | |
NO963331L (no) | 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister | |
DE50008020D1 (de) | Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten | |
FR2690847B1 (fr) | Compositions a activite agoniste des recepteurs analogues a 5ht1 selective. | |
ES2172939T3 (es) | Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores. | |
NO20000654D0 (no) | 1,3-dioxolo/4,5-H//2,3/benzodiazepinderivater som AMPA/KAINAT reseptorinhibitorer | |
ECSP972049A (es) | Derivados de lactama |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 984963 Country of ref document: ES |